John L. Dzuris, Ph.D.
EXECUTIVE DIRECTOR OF IMMUNOLOGY
John L. Dzuris has over twenty years diverse experience in drug discovery and translational research that he brings with him to Nirogy Therapeutics as the Executive Director of Immunology. He has applied biological and molecular approaches to study and identify different classes of immune modulating therapeutics for the treatment of infectious diseases, oncology, and autoimmune diseases. John received his B.S. degree in Microbiology from The Ohio State University, and then earned his M.S. degree in Microbiology from Louisiana State University. He attended Temple University Lewis Katz School of Medicine in Philadelphia, PA receiving his Ph.D. in the Department of Microbiology and Immunology. He continued his immunology training with a Postdoctoral Fellowship at the University of Pennsylvania School of Medicine in Philadelphia, PA. His graduate and postdoctoral studies concentrated on retroviral and host immune response interactions. John then joined the staff at Epimmune, Inc. in San Diego, CA helping to develop DNA and peptide-based vaccines for oncology and infectious diseases. His work at Epimmune also established immune response similarities between human and non-human primate, which were utilized for pre-clinical evaluation of vaccine efficacy. After joining the staff at Wyeth Corporation for a short period as a Senior Scientist in the Department of Viral Immunology, John was then recruited to join Genzyme Corporation in 2002. There he established a Cellular Immunology group in Discovery Research and spent nearly 10 years at Genzyme. His work focused on evaluating small molecule drugs and biotherapeutics for immune modulation in oncology, transplant and autoimmune disease and the identification of new drug targets and biomarkers using a proteomic platform. John’s leadership continued as Director of Immunology and Lab Head at ImmusanT and then Senior Director at Biohaven Pharmaceuticals, overseeing both pre-clinical and clinical stage immune evaluations of biotherapeutics for autoimmune disease, oncology, and infectious disease.